Drug intelligence / Profile preview

budesonide + salmeterol + montelukast

Development stage: Preclinical
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Inhalation, Oral

Overview

A combination therapy consisting of budesonide (an inhaled corticosteroid), salmeterol (a long-acting beta-agonist), and montelukast (a leukotriene receptor antagonist). This combination targets multiple pathways involved in asthma and respiratory conditions. Budesonide provides anti-inflammatory effects, salmeterol helps with bronchodilation and smooth muscle relaxation, while montelukast blocks leukotriene-mediated inflammation.

Targets

CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)ADRB2 (β2)

Beyond the preview

Go deeper on budesonide + salmeterol + montelukast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on budesonide + salmeterol + montelukast.

Explore the full profile